» Articles » PMID: 21443771

Characteristics of Non-AIDS-defining Malignancies in the HAART Era: a Clinico-epidemiological Study

Overview
Journal J Int AIDS Soc
Date 2011 Mar 30
PMID 21443771
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Non-AIDS-defining malignancies (NADM) are becoming a major cause of mortality in the era of highly active antiretroviral therapy. We wished to investigate the incidence, risks factors and outcome of NADM in an urban cohort.

Methods: We carried out an observational cohort of HIV patients with 12,746 patient-years of follow up between January 2002 and March 2009. Socio-demographics and clinical characteristics of patients diagnosed with NADM were retrospectively compared with the rest of the cohort. Causes of death and risk factors associated with NADM were assessed using logistic regression. Survival analyses were performed with Kaplan-Meier estimates. Cancer incidences were compared with those of the general population of the Brussels-Capital Region using the standardized incidence ratio (SIR).

Results: Forty-five NADM were diagnosed. At inclusion in the study, patients with NADM were older than patients without NADM (47 years vs. 38 years, p < 0.001), had a longer history of HIV infection (59 months vs. 39 months, p = 0.0174), a lower nadir CD4 count (110 cells/mm3 vs. 224 cells/mm3, p < 0.0001) and a higher rate of previous AIDS events (33% vs. 20%, p = 0.0455) and of hepatitis C virus co-infection (22.2% vs. 10%, p = 0.0149). In multivariate analysis, age over 45 at baseline (OR 3.25; 95% CI 1.70-6.22) and a nadir CD4 count of less than 200 cells/mm3 (OR 3.10; 95% CI 1.40-6.87) were associated with NADM. NADM were independently associated with higher mortality in the cohort (OR 14.79; 95% CI 6.95-31.49). Women with cancer, the majority of whom were of sub-Saharan African origin, had poorer survival compared with men. The SIR for both sexes were higher than expected for Hodgkin's lymphoma (17.78; 95% CI 6.49-38.71), liver cancers (8.73; 95% CI 2.35-22.34), anal cancers (22.67; 95% CI 8.28-49.34) and bladder cancers (3.79; 95% CI 1.02-9.70). The SIR for breast cancer was lower in women (SIR 0.29; 95% CI 0.06-0.85).

Conclusions: Age over 45 and a nadir CD4 count of less than 200 cells/mm3 were predictive of NADM in our cohort. Mortality was high, especially in sub-Saharan African women. Cancers with increased incidences were Hodgkin's lymphoma and anal, bladder and liver cancers in both sexes; women had a lower incidence of breast cancer.

Citing Articles

A New Start with HAART: Evaluating Breast Reconstruction in the Era of Highly Active Antiretroviral Therapy.

Amakiri U, Shah J, Akhter M, Fung E, Sheckter C, Nazerali R Plast Reconstr Surg Glob Open. 2024; 12(8):e6040.

PMID: 39114797 PMC: 11305706. DOI: 10.1097/GOX.0000000000006040.


The Trends and Risk Factors of AIDS-Defining Cancers and Non-AIDS-Defining Cancers in Adults Living with and without HIV: A Narrative Review.

Mathoma A, Sartorius B, Mahomed S J Cancer Epidemiol. 2024; 2024:7588928.

PMID: 38549952 PMC: 10978085. DOI: 10.1155/2024/7588928.


Association of CD4 + cell count and HIV viral load with risk of non-AIDS-defining cancers.

Ma Y, Zhang J, Yang X, Chen S, Weissman S, Olatosi B AIDS. 2023; 37(13):1949-1957.

PMID: 37382882 PMC: 10538428. DOI: 10.1097/QAD.0000000000003637.


Incidence and mortality of non-AIDS-defining cancers among people living with HIV: A systematic review and meta-analysis.

Yuan T, Hu Y, Zhou X, Yang L, Wang H, Li L EClinicalMedicine. 2022; 52:101613.

PMID: 35990580 PMC: 9386399. DOI: 10.1016/j.eclinm.2022.101613.


Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis.

Platt L, French C, McGowan C, Sabin K, Gower E, Trickey A J Viral Hepat. 2019; 27(3):294-315.

PMID: 31603999 PMC: 7383613. DOI: 10.1111/jvh.13217.


References
1.
Clifford G, Franceschi S . Cancer risk in HIV-infected persons: influence of CD4(+) count. Future Oncol. 2009; 5(5):669-78. DOI: 10.2217/fon.09.28. View

2.
Hessol N, Pipkin S, Schwarcz S, Cress R, Bacchetti P, Scheer S . The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol. 2007; 165(10):1143-53. DOI: 10.1093/aje/kwm017. View

3.
Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B . Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2008; 27(6):884-90. DOI: 10.1200/JCO.2008.19.6626. View

4.
Phillips A, Justman J . Screening HIV-infected patients for non-AIDS-defining malignancies. Curr HIV/AIDS Rep. 2009; 6(2):83-92. DOI: 10.1007/s11904-009-0013-0. View

5.
Luker K, Luker G . Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett. 2005; 238(1):30-41. DOI: 10.1016/j.canlet.2005.06.021. View